US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Veraxa Biotech Holding AG

1.46

-0.0100-0.68%

Post-market: 1.460.00000.00%16:10 EDT

Volume:16.38K

Turnover:24.11K

Market Cap:206.46M

PE:6.82

High:1.52

Open:1.50

Low:1.45

Close:1.47

52wk High:27.36

52wk Low:1.27

Shares:141.41M

Float Shares:40.96M

Volume Ratio:0.27

T/O Rate:0.04%

Dividend:- -

Dividend Rate:- -

EPS(TTM):0.2142

EPS(LYR):-5.8037

ROE:-871.42%

ROA:-49.99%

PB:-10.77

PE(LYR):-0.25

Loading ...

Overview Company News Filings

VERAXA Biotech (NASDAQ: VRXA) Advances Lead BiTAC(R) T-Cell Engager Program with Cell Line Development Partnership

VERAXA Biotech (NASDAQ: VRXA) Shareholders Should Watch Novartis Latest $1.5B ADC Acquisition

Veraxa Biotech Proposes Raising Conditional Capital Ceiling to CHF 459,789 Via Bylaw Change

VERAXA Biotech (NASDAQ: VRXA) Highlights BiTAC Pipeline Progress, Advances Partnering Strategy

Veraxa Biotech provides pipeline and partnering strategy update

Veraxa Biotech Ag - Targets Vxa-102 Ind/cta-ready by Beginning of 2028

THOMSON REUTERS

Veraxa Biotech Ag - to Focus Investments on Bitac Portfolio and Monetize Non-bitac Assets

THOMSON REUTERS

Veraxa Biotech Provides Business Update and Further Details on Partnering Strategy and Development Timelines

THOMSON REUTERS

VERAXA Biotech Provides Business Update and Further Details on Partnering Strategy and Development Timelines

VERAXA Biotech (NASDAQ: VRXA) Initiates Cell Line Development for Lead BiTAC Cancer Therapy Program

Veraxa Collaborates With ATUM on Cell Line Development for BiTAC T-Cell Engager Program

MT Newswires Live

Veraxa Biotech Initiates Cell Line Development with Atum to Advance Its Lead Bitac®-tce Program

THOMSON REUTERS

Why VERAXA Biotech (NASDAQ: VRXA) Shareholders Should Pay Serious Attention to Antibody Therapeutics Sector Deals

VERAXA Biotech (NASDAQ: VRXA) Advances BiTAC-ADC Platform as It Expands Next-Generation Cancer Therapy Pipeline

VERAXA Biotech (NASDAQ: VRXA) Expands Heidelberg R&D Facilities To Support Drug Development Pipeline

Veraxa Biotech expands R&D site in Germany

VERAXA Biotech Expands R&D Hub in Heidelberg as Innovative BiTAC™-TCE and ADC Programs Advance Towards Clinical Development

VERAXA Biotech (NASDAQ: VRXA) Showcases BiTAC Cancer Platforms Ahead of BIO International Convention

Veraxa Biotech Establishes in Vitro Proof-of-Concept for Novel Bitac-ADC Technology Platform and Launches Partnering Discussions at Bio International Convention 2026

THOMSON REUTERS

VERAXA Biotech Establishes in vitro Proof-of-Concept for Novel BiTAC-ADC Technology Platform and Launches Partnering Discussions at BIO International Convention 2026

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigerfiesta.com/stock/VRXA/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"VRXA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"VRXA\",,,,,undefined,":{"symbol":"VRXA","market":"US","secType":"STK","nameCN":"Veraxa Biotech Holding AG","latestPrice":1.46,"timestamp":1789761600000,"preClose":1.47,"halted":0,"volume":16375,"hourTrading":{"tag":"盘后","latestPrice":1.46,"preClose":1.46,"latestTime":"16:10 EDT","volume":8,"amount":11.68,"timestamp":1789762204697,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.00680272108843538,"floatShares":40957496,"shares":141407813,"eps":0.2142,"marketStatus":"Market Closed","change":-0.01,"latestTime":"09-18 16:00:00 EDT","open":1.5,"high":1.5152,"low":1.45,"amount":24112,"amplitude":0.044354,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.2142,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1789977600000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":1.47,"preHourTrading":{"tag":"盘前","latestPrice":1.47,"preClose":1.47,"latestTime":"09:29 EDT","volume":187,"amount":277.9395025,"timestamp":1789738199018,"change":0,"changeRate":0,"amplitude":0.069456},"postHourTrading":{"tag":"盘后","latestPrice":1.46,"preClose":1.46,"latestTime":"16:10 EDT","volume":8,"amount":11.68,"timestamp":1789762204697,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.27163905691128976},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"VRXA\",,,,,undefined,":{"symbol":"VRXA","floatShares":40957496,"roa":"-49.99%","roe":"-871.42%","lyrEps":-5.803658,"volumeRatio":0.27163905691128976,"shares":141407813,"dividePrice":0,"high":1.5152,"amplitude":0.044354,"preClose":1.47,"low":1.45,"week52Low":1.27,"pbRate":"-10.77","psRate":"7248.74","week52High":27.36,"institutionHeld":0,"latestPrice":1.46,"eps":0.2142,"divideRate":0,"volume":16375,"delay":0,"ttmEps":0.2142,"open":1.5,"prevYearClose":18.65,"prevWeekClose":1.65,"prevMonthClose":1.35,"prevQuarterClose":1.88,"fiveDayClose":1.65,"twentyDayClose":1.89,"sixtyDayClose":2.3},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/VRXA\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"VRXA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"VRXA\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/VRXA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"VRXA","date":"2026-09-18","current":6.81606,"percent":0.45,"low":-3.022108,"twenty":-2.751957,"median":-2.365287,"eighty":-1.181392,"high":-0.413162,"avg":-1.904414,"sd":0.904601,"marketCap":207869485},"quantilePoints":[{"date":"2026-08-21","current":-1.35335,"twenty":-1.349054,"median":-1.34261,"eighty":-1.336165,"marketCap":47660725},{"date":"2026-08-28","current":-1.03732,"twenty":-1.349054,"median":-1.281094,"eighty":-1.194963,"marketCap":36312933},{"date":"2026-09-04","current":-2.622384,"twenty":-1.391748,"median":-1.265172,"eighty":-0.552029,"marketCap":216353953},{"date":"2026-09-11","current":-2.842124,"twenty":-2.738773,"median":-1.34261,"eighty":-1.03732,"marketCap":233322891},{"date":"2026-09-18","current":-2.57236,"twenty":-2.751957,"median":-2.365287,"eighty":-1.181392,"marketCap":207869485}],"updateTime":1789856073996},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"VRXA\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2650975096","title":"VERAXA Biotech (NASDAQ: VRXA) Advances Lead BiTAC(R) T-Cell Engager Program with Cell Line Development Partnership","url":"https://stock-news.laohu8.com/highlight/detail?id=2650975096","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650975096?lang=en_us&edition=fundamental","pubTime":"2026-07-10 01:00","pubTimestamp":1783616408,"startTime":"0","endTime":"0","summary":"Austin, Texas, United States, July 9th, 2026, FinanceWire The company has initiated cell line development for its lead BiTAC(R) T-cell engager prog...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/newswire/veraxa-biotech-nasdaq-vrxa-advances-lead-bitacr-t-cell-engager-program-with-cell-line-development-partnership?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/newswire/veraxa-biotech-nasdaq-vrxa-advances-lead-bitacr-t-cell-engager-program-with-cell-line-development-partnership?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["R","QDTE","BK4585","QQQE","JEPQ","QQQJ","SQQQ","TQQY","BK4581","QQQ","GPIQ","TECS","BK4139","PSQ","NDX","QQQA","QQQM","XBI","QLD","IYW",".IXIC","QYLG","ONEQ","BK4022","BK4588","TQQQ","BK4232","MNQmain","DBB","NVIW.SI","NQmain","QID","VRXA","QQQY","FTEC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649931305","title":"VERAXA Biotech (NASDAQ: VRXA) Shareholders Should Watch Novartis Latest $1.5B ADC Acquisition","url":"https://stock-news.laohu8.com/highlight/detail?id=2649931305","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649931305?lang=en_us&edition=fundamental","pubTime":"2026-07-08 00:30","pubTimestamp":1783441807,"startTime":"0","endTime":"0","summary":"Austin, Texas, United States, July 7th, 2026, FinanceWire Novartis has agreed to acquire Myricx Bio for $1.1 billion upfro...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/newswire/veraxa-biotech-nasdaq-vrxa-shareholders-should-watch-novartis-latest-1-5b-adc-acquisition?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/newswire/veraxa-biotech-nasdaq-vrxa-shareholders-should-watch-novartis-latest-1-5b-adc-acquisition?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["QQQJ","QDTE","TQQQ","VRXA","FTEC","PSQ","QQQE","JEPQ","ADC","QLD","QID","NETL","BK4139","XBI","NVIW.SI","ONEQ","QQQ","BK4581","BK4588","BK4231","GPIQ","BK4080","QYLG","NDX",".IXIC","MNQmain","SQQQ","QQQY","IYW","TQQY","BK4585","QQQA","NQmain","QQQM","TECS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649291679","title":"Veraxa Biotech Proposes Raising Conditional Capital Ceiling to CHF 459,789 Via Bylaw Change","url":"https://stock-news.laohu8.com/highlight/detail?id=2649291679","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649291679?lang=en_us&edition=fundamental","pubTime":"2026-07-07 04:11","pubTimestamp":1783368675,"startTime":"0","endTime":"0","summary":"Veraxa Biotech proposes raising conditional capital ceiling to CHF 459,789 via bylaw changeVeraxa Biotech set a July 24, 2026 extraordinary shareholder vote on bylaw changes expanding its equity issua","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260706:nNDLblPcHf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VRXA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649753526","title":"VERAXA Biotech (NASDAQ: VRXA) Highlights BiTAC Pipeline Progress, Advances Partnering Strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=2649753526","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649753526?lang=en_us&edition=fundamental","pubTime":"2026-07-07 01:00","pubTimestamp":1783357208,"startTime":"0","endTime":"0","summary":"Austin, Texas, United States, July 6th, 2026, FinanceWire VERAXA Biotech (NASDAQ:VRXA) provided a corporate and pipeline update highlighting p...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/newswire/veraxa-biotech-nasdaq-vrxa-highlights-bitac-pipeline-progress-advances-partnering-strategy?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/newswire/veraxa-biotech-nasdaq-vrxa-highlights-bitac-pipeline-progress-advances-partnering-strategy?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ONEQ","QQQM","QID","TQQQ","QQQE","TQQY","NDX","BK4139",".IXIC","IYW","QQQY","QYLG","LU2065732104.USD","BK4585","MNQmain","BK4097","FTEC","PRGS","PSQ","SQQQ","JEPQ","VRXA","BK4581","TECS","BK4588","NQmain","QQQA","NVIW.SI","QDTE","GPIQ","QQQJ","QLD","XBI","QQQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649242006","title":"Veraxa Biotech provides pipeline and partnering strategy update","url":"https://stock-news.laohu8.com/highlight/detail?id=2649242006","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649242006?lang=en_us&edition=fundamental","pubTime":"2026-07-06 21:15","pubTimestamp":1783343707,"startTime":"0","endTime":"0","summary":"Veraxa Biotech (VRXA) provided a company and pipeline update, highlighting its strategic focus on its proprietary BiTAC platform. The company inten...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/veraxa-biotech-provides-pipeline-and-partnering-strategy-update-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/veraxa-biotech-provides-pipeline-and-partnering-strategy-update-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VRXA","BK4585","XBI","BK4581","BK4139","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649625646","title":"Veraxa Biotech Ag - Targets Vxa-102 Ind/cta-ready by Beginning of 2028","url":"https://stock-news.laohu8.com/highlight/detail?id=2649625646","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649625646?lang=en_us&edition=fundamental","pubTime":"2026-07-06 19:00","pubTimestamp":1783335602,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260706:nTUA5CXFFC:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VRXA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649625627","title":"Veraxa Biotech Ag - to Focus Investments on Bitac Portfolio and Monetize Non-bitac Assets","url":"https://stock-news.laohu8.com/highlight/detail?id=2649625627","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649625627?lang=en_us&edition=fundamental","pubTime":"2026-07-06 19:00","pubTimestamp":1783335602,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260706:nTUA5CXFFC:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VRXA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649256786","title":"Veraxa Biotech Provides Business Update and Further Details on Partnering Strategy and Development Timelines","url":"https://stock-news.laohu8.com/highlight/detail?id=2649256786","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649256786?lang=en_us&edition=fundamental","pubTime":"2026-07-06 19:00","pubTimestamp":1783335602,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260706:nTUA5CXFFC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VRXA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649267546","title":"VERAXA Biotech Provides Business Update and Further Details on Partnering Strategy and Development Timelines","url":"https://stock-news.laohu8.com/highlight/detail?id=2649267546","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649267546?lang=en_us&edition=fundamental","pubTime":"2026-07-06 19:00","pubTimestamp":1783335600,"startTime":"0","endTime":"0","summary":"Novel conditionally active T cell engagers sourced from proprietary BiTAC platform are at the basis of advanced partnering initiatives and development activitiesZURICH, SWITZERLAND – July 6, 2026 -- V","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/06/3322298/0/en/VERAXA-Biotech-Provides-Business-Update-and-Further-Details-on-Partnering-Strategy-and-Development-Timelines.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VRXA","BK4581","BK4585","BK4139","XBI","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648368411","title":"VERAXA Biotech (NASDAQ: VRXA) Initiates Cell Line Development for Lead BiTAC Cancer Therapy Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2648368411","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648368411?lang=en_us&edition=fundamental","pubTime":"2026-07-03 01:00","pubTimestamp":1783011614,"startTime":"0","endTime":"0","summary":"Austin, Texas, United States, July 2nd, 2026, FinanceWire VERAXA Biotech (NASDAQ:VRXA) announced the initiation of cell line development for i...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/newswire/veraxa-biotech-nasdaq-vrxa-initiates-cell-line-development-for-lead-bitac-cancer-therapy-program?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/newswire/veraxa-biotech-nasdaq-vrxa-initiates-cell-line-development-for-lead-bitac-cancer-therapy-program?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":[".IXIC","BK4585","BK4581","BK4588","PSQ","TQQY","XBI","ONEQ","QQQ","IYW","QLD","BK4139","QQQY","JEPQ","FTEC","QDTE","GPIQ","QQQE","NQmain","QQQA","VRXA","NDX","QID","TQQQ","TECS","MNQmain","QQQM","DBB","QYLG","QQQJ","SQQQ","NVIW.SI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648040085","title":"Veraxa Collaborates With ATUM on Cell Line Development for BiTAC T-Cell Engager Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2648040085","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648040085?lang=en_us&edition=fundamental","pubTime":"2026-07-02 19:39","pubTimestamp":1782992371,"startTime":"0","endTime":"0","summary":"Veraxa Biotech  said Thursday it has engaged US contract research organization ATUM to begin cell line development for its lead BiTAC T-cell engager program.The company said ATUM will support the generation of stable clonal cell lines using its Leap-In Transposase technology.The company said the cell lines will be used throughout CMC development, including early process, analytical testing, formulation work, and production of material for nonclinical studies.Veraxa said its BiTAC-TCE platform is designed to improve the safety of T-cell engager therapies by activating T-cells only when two tumor markers are present on the same cell, reducing the risk of attacking healthy tissue.Shares of Veraxa Biotech were up more than 3% in premarket activity Thursday.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["VRXA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648014435","title":"Veraxa Biotech Initiates Cell Line Development with Atum to Advance Its Lead Bitac®-tce Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2648014435","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648014435?lang=en_us&edition=fundamental","pubTime":"2026-07-02 19:00","pubTimestamp":1782990017,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260702:nFWN4340EX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","VRXA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648654021","title":"Why VERAXA Biotech (NASDAQ: VRXA) Shareholders Should Pay Serious Attention to Antibody Therapeutics Sector Deals","url":"https://stock-news.laohu8.com/highlight/detail?id=2648654021","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648654021?lang=en_us&edition=fundamental","pubTime":"2026-07-02 01:30","pubTimestamp":1782927021,"startTime":"0","endTime":"0","summary":"Austin, Texas, United States, July 1st, 2026, FinanceWire Deal activity remains strong in antibody-drug conjugates (ADCs) and T-cell engager (TCE) ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/newswire/why-veraxa-biotech-nasdaq-vrxa-shareholders-should-pay-serious-attention-to-antibody-therapeutics-sector-deals?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/newswire/why-veraxa-biotech-nasdaq-vrxa-shareholders-should-pay-serious-attention-to-antibody-therapeutics-sector-deals?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":[".IXIC","IYW","TQQY","QLD","GPIQ","BK4007","TQQQ","FTEC","ONEQ","XBI","LENZ","VRXA","BK4588","NVIW.SI","JEPQ","NQmain","QQQJ","QYLG","TECS","SQQQ","QID","QQQA","QDTE","BK4581","QQQM","BK4139","BK4539","BK4585","MNQmain","QQQ","PSQ","NDX","QQQY","QQQE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646388644","title":"VERAXA Biotech (NASDAQ: VRXA) Advances BiTAC-ADC Platform as It Expands Next-Generation Cancer Therapy Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2646388644","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646388644?lang=en_us&edition=fundamental","pubTime":"2026-06-26 02:30","pubTimestamp":1782412223,"startTime":"0","endTime":"0","summary":"Austin, Texas, United States, June 25th, 2026, FinanceWire VERAXA Biotech has reported new in vitro proof-of-concept data supporting its BiTAC-ADC ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/newswire/veraxa-biotech-nasdaq-vrxa-advances-bitac-adc-platform-as-it-expands-next-generation-cancer-therapy-pipeline?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/newswire/veraxa-biotech-nasdaq-vrxa-advances-bitac-adc-platform-as-it-expands-next-generation-cancer-therapy-pipeline?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4080","QQQM",".IXIC","VRXA","MNQmain","GPIQ","NDX","QID","TQQQ","PSQ","BK4231","QLD","JEPQ","QQQY","BK4585","QYLG","TECS","BK4588","QQQJ","BK4581","QDTE","SQQQ","XBI","QQQE","QQQA","QQQ","NVIW.SI","BK4139","TQQY","ADC","ONEQ","FTEC","NQmain","IYW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646106488","title":"VERAXA Biotech (NASDAQ: VRXA) Expands Heidelberg R&D Facilities To Support Drug Development Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2646106488","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646106488?lang=en_us&edition=fundamental","pubTime":"2026-06-25 02:00","pubTimestamp":1782324016,"startTime":"0","endTime":"0","summary":"Austin, Texas, United States, June 24th, 2026, FinanceWire VERAXA Biotech (NASDAQ:VRXA) an emerging developer of novel cancer therapies, annou...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/newswire/veraxa-biotech-nasdaq-vrxa-expands-heidelberg-rd-facilities-to-support-drug-development-pipeline?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/newswire/veraxa-biotech-nasdaq-vrxa-expands-heidelberg-rd-facilities-to-support-drug-development-pipeline?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["QQQY","BK4139","PSQ",".IXIC","NDX","IYW","QQQA","BK4588","TECS","BK4581","QQQJ","QQQE","QQQM","QYLG","BK4585","FTEC","QID","QQQ","TQQY","XBI","VRXA","JEPQ","SQQQ","NVIW.SI","QLD","QDTE","MNQmain","TQQQ","GPIQ","NQmain","ONEQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645976338","title":"Veraxa Biotech expands R&D site in Germany","url":"https://stock-news.laohu8.com/highlight/detail?id=2645976338","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645976338?lang=en_us&edition=fundamental","pubTime":"2026-06-24 19:10","pubTimestamp":1782299426,"startTime":"0","endTime":"0","summary":"Veraxa Biotech (VRXA) announced that the company has moved into additional laboratory space at its existing R&D site in Heidelberg, Germany, based ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/veraxa-biotech-expands-rd-site-in-germany-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/veraxa-biotech-expands-rd-site-in-germany-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","XBI","UFO","BK4564","BK4581","ARKX","BK4544","VRXA","BK4585","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645784892","title":"VERAXA Biotech Expands R&D Hub in Heidelberg as Innovative BiTAC™-TCE and ADC Programs Advance Towards Clinical Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2645784892","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645784892?lang=en_us&edition=fundamental","pubTime":"2026-06-24 19:00","pubTimestamp":1782298800,"startTime":"0","endTime":"0","summary":"Greater than 60% increase in laboratory space will strengthen R&D capabilities, facilitate acceleration toward clinical development, and increase ability to tap into Heidelberg’s world-class medical o","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/24/3316702/0/en/VERAXA-Biotech-Expands-R-D-Hub-in-Heidelberg-as-Innovative-BiTAC-TCE-and-ADC-Programs-Advance-Towards-Clinical-Development.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","HUBG","BK4581","BK4080","IE00B66KJ199.SGD","BK4231","BK4139","IE00B7SZL793.SGD","IE0031619046.USD","IE00B19Z4B17.USD","XBI","ADC","VRXA","BK4585","BK4131"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645076533","title":"VERAXA Biotech (NASDAQ: VRXA) Showcases BiTAC Cancer Platforms Ahead of BIO International Convention","url":"https://stock-news.laohu8.com/highlight/detail?id=2645076533","media":"TIPRANKS","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645076533?lang=en_us&edition=fundamental","pubTime":"2026-06-22 23:30","pubTimestamp":1782142206,"startTime":"0","endTime":"0","summary":"Austin, Texas, United States, June 22nd, 2026, FinanceWire VERAXA Biotech (NASDAQ:VRXA) is highlighting partnering opportunities for its propr...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/newswire/veraxa-biotech-nasdaq-vrxa-showcases-bitac-cancer-platforms-ahead-of-bio-international-convention?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/newswire/veraxa-biotech-nasdaq-vrxa-showcases-bitac-cancer-platforms-ahead-of-bio-international-convention?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FTEC","BK4581","QYLG","TECS","NDX","QDTE","IYW","BK4585","BK4139","QQQA","QQQM","QQQY","VRXA","LU1169590202.USD",".IXIC","BIO","JEPQ","MNQmain","BK4588","NVIW.SI","GPIQ","NQmain","LU1169589451.USD","QQQE","QID","PSQ","TQQQ","QLD","BK4121","QQQ","TQQY","XBI","ONEQ","SQQQ","QQQJ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644794707","title":"Veraxa Biotech Establishes in Vitro Proof-of-Concept for Novel Bitac-ADC Technology Platform and Launches Partnering Discussions at Bio International Convention 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2644794707","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644794707?lang=en_us&edition=fundamental","pubTime":"2026-06-18 19:00","pubTimestamp":1781780400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260618:nTUAB2N08L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VRXA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644570063","title":"VERAXA Biotech Establishes in vitro Proof-of-Concept for Novel BiTAC-ADC Technology Platform and Launches Partnering Discussions at BIO International Convention 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2644570063","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644570063?lang=en_us&edition=fundamental","pubTime":"2026-06-18 19:00","pubTimestamp":1781780400,"startTime":"0","endTime":"0","summary":"BiTAC-ADC in vitro data, along with initial data from the most advanced BiTAC-TCE program recently presented at the American Association for Cancer Research (AACR) Annual Meeting, underpin the Company","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/18/3314047/0/en/VERAXA-Biotech-Establishes-in-vitro-Proof-of-Concept-for-Novel-BiTAC-ADC-Technology-Platform-and-Launches-Partnering-Discussions-at-BIO-International-Convention-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1169590202.USD","BK4581","BIO","ADC","BK4080","BK4588","LU1169589451.USD","BK4121","BK4585","VRXA","BK4231","XBI"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":3,"totalSize":74,"code":"91000000","status":"200"}]}}